Home > News > Insert Therapeutics Files IND Application
February 9th, 2006
Insert Therapeutics Files IND Application
Abstract:
Arrowhead Research Corporation (Nasdaq:ARWR) announced today that its majority-owned subsidiary Insert Therapeutics, Inc. has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for IT-101, its first anti-cancer drug candidate. Cyclosert is a proprietary drug delivery technology based on a nano-engineered class of linear cyclodextrin polymers.
Source:
businesswire
Bookmark:
| Related News Press |
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
Decoding hydrogen‑bond network of electrolyte for cryogenic durable aqueous zinc‑ion batteries January 30th, 2026
COF scaffold membrane with gate‑lane nanostructure for efficient Li+/Mg2+ separation January 30th, 2026
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||